Theranostics is a treatment approach that combines diagnosis and therapy, using radioactive drugs (radiopharmaceuticals) to deliver targeted care.
Pluvicto is a radiopharmaceutical drug specifically designed to treat prostate cancer. It is designed to seek out prostate cancer cells that express PSMA (prostate-specific membrane antigen) that were also identified through diagnostic imaging. Once these cells are identified, treatment is delivered directly to cells to destroy the cancer and spare damage to surrounding healthy tissue.
How Pluvicto Works
Pluvicto, a radiopharmaceutical drug, contains a targeting molecule that specifically binds to PSMA (prostate-specific membrane antigen), a protein found at high levels on prostate cancer cells. The molecule attaches to the prostate cancer cells, where it is absorbed and releases targeted radiation from inside the cell to damage and kill the cancer, without damaging surrounding healthy tissue.